Atlas Trials

Refractory Transformed B-Cell Non-Hodgkin Lymphoma

9 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Refractory Transformed B-Cell Non-Hodgkin Lymphoma

RecordFirmDate
Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma (NCT05202782)Northwestern University2022-03-21
Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy (NCT04703686)The Lymphoma Academic Research Organisation2021-03-30
Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT04665765)City of Hope Medical Center2021-01-18
Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (NCT03309878)National Cancer Institute (NCI)2018-10-24
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas (NCT03277729)Fred Hutchinson Cancer Center2017-12-05
Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma (NCT02207062)University of Washington2014-10-01

Track Refractory Transformed B-Cell Non-Hodgkin Lymphoma automatically

Every clearance here is in the API, with alerts when new ones post.